EXPRESSION OF ROTAVIRUS OUTER CAPSID PROTEIN VP4 BY RECOMBINANT ADENOVIRUS

轮状病毒是婴儿和青少年严重腹泻的主要原因 发达国家和发展中国家的儿童。 因此，密集 正在努力开发有效的疫苗。 两个外衣壳 轮状病毒蛋白 VP7 或 VP4 均与诱导 中和抗体已在实验动物中显示 与对疾病的抵抗力有关。 血清型特异性已 与 VP7 相关。 然而，最近的研究已经开始阐明 基于抗原性的人类轮状病毒之间的抗原关系 VP4 蛋白的特异性。 人类轮状病毒株 与症状感染相关并表现出 VP7 特异性 血清型 1、2、3、4 或 9 各自具有相似的 VP4，如 中和测定。 我们选择猪轮状病毒OSU的外衣壳蛋白VP4作为 研究该蛋白在腺病毒载体中的免疫原性的模型。 腺病毒口服给药的能力使其具有潜在的用途 腺病毒载体用于疫苗生产特别有吸引力。 在 此外，腺病毒疫苗已被证明对人类是安全的 当以肠溶胶囊或片剂口服给药时。

Rotaviruses are the major cause of severe diarrhea in infants and young children in both developed and developing countries. Therefore, intensive efforts are being made to develop an effective vaccine. Two outer capsid rotavirus proteins, VP7 or VP4, are each associated with the induction of neutralizing antibodies that have been shown in experimental animals to be associated with resistance to illness. Serotype specificity has been associated with VP7. However, recent studies have begun to elucidate the antigenic relationships among human rotaviruses based on the antigenic specificity of the VP4 protein as well. Human rotavirus strains that were associated with symptomatic infection and that exhibited VP7 specificity of serotype 1, 2, 3, 4, or 9 each possessed a similar VP4 as determined by neutralization assay. We have chosen the outer capsid protein VP4 of porcine rotavirus OSU as a model to study the immunogenicity of this protein in an adenovirus vector. The ability of adenovirus to be administered orally makes the potential use of adenovirus vectors for vaccine production particularly attractive. In addition, adenovirus vaccines have already been shown to be safe in humans when administered orally as enteric coated capsules or tablets.